- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01637233
MARCH Central Nervous System Substudy
Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N(t)RTI) or Boosted Protease Inhibitors (PI/r) in HIV-1 Infected Individuals With Stable, Well-controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of Combination Antiretroviral Therapy (cART).
This substudy is a prospective, observational, open-label, randomised study within the MARCH study. The purpose of this substudy is to investigate the changes in cerebral function parameters at 5 timepoints over 96 weeks of the three different treatment arms within the MARCH study. The investigators hypothesise that there will be improvements in cerebral function in those patients randomised, as part of the parent study, into the maraviroc arms.
the assessments in this CNS substudy will include:
- Neurocognitive function as assessed by a computerised testing battery called CogState;
- changes in cerebral metabolites as measured via 1H Magnetic Resonance Spectroscopy (1H-MRS)
In those randomised to the maraviroc arms (arms 2 and 3) there is an optional Lumbar puncture at week 48. The cerebrospinal fluid will be used to measure maraviroc levels and an ultrasensitive CSF HIV-1 viral load. These results will be matched with levels in the plasma.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1405CKC
- Fundacion IDEAA
-
Buenos Aires, Argentina, C1221ADC
- Hospital Ramos Mejía
-
Rosario, Argentina
- CAICI
-
-
-
-
-
London, Det Forenede Kongerige, W2
- Imperial Healthcare, St. Mary's Hospital
-
-
Sussex
-
Brighton, Sussex, Det Forenede Kongerige, BN21ES,
- Brighton & Sussex University NHS Trust
-
-
-
-
-
Bangkok, Thailand, 10330
- Chulalongkorn University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Provision of written, informed consent for participation in the substudy
- Enrolled into the substudy either at or before the week 0 visit of the main study
Exclusion Criteria:
- Pre-existing CNS diseases
- Recent head injury (past three months)
- Current history of major depression or psychosis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
NRTI + PI
This is the randomisation of the main study, Arm 1
|
Medicin: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors
NRTI+PI
Andre navne:
|
maraviroc + PI
this is the randomisation of the main study, Arm 2
|
maraviroc + PI
Andre navne:
|
maraviroc + NRTI
this is the randomisation of the main study, Arm 3
|
maraviroc + NRTI
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
To assess changes in NC function over 96 weeks, measured via a computerised testing battery in HIV-infected subjects stable on antiretroviral therapy randomised to three different treatment approaches
Tidsramme: 96 weeks
|
using CogState testing at 5 timepoints, weeks 0, 12, 24, 48, 96
|
96 weeks
|
To assess changes in cerebral metabolites over 96 weeks, measured via 1H Magnetic Resonance Spectroscopy (1H-MRS), in HIV-infected subjects stable on antiretroviral therapy randomised to three different treatment approaches
Tidsramme: 96 weeks
|
Assessment of CNS metabolites via 1H-MRS at week 0, 48, 96
|
96 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
to assess CSF HIV-1 RNA and CSF maraviroc concentration (in the MVC treatment arms) versus plasma HIV -1 RNA and MVC concentration after 48 weeks of therapy
Tidsramme: 48 weeks
|
A LP examination at week 48 (optional and only in the MVC treatment arms, and only if there is no contraindication to LP) to assess, with matched plasma samples:
|
48 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Alan Winston, MD, Imperial Healthcare, London, UK
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Infektioner
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Anti-HIV-midler
- Anti-retrovirale midler
- Antimetabolitter
- Cytokrom P-450 CYP3A-hæmmere
- Cytokrom P-450 enzymhæmmere
- Virale proteasehæmmere
- HIV-fusionshæmmere
- Virale fusionsproteinhæmmere
- CCR5-receptorantagonister
- Tenofovir
- Emtricitabin
- Ritonavir
- Lopinavir
- Lamivudin
- Zidovudin
- Proteasehæmmere
- Maraviroc
- Reverse transkriptasehæmmere
- Darunavir
- Atazanavirsulfat
- Abacavir
- Dideoxynukleosider
- Fosamprenavir
- HIV-proteasehæmmere
Andre undersøgelses-id-numre
- MARCH-Kirby CNS
- 2011-002107-15 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV-1 infektion
-
Helios SaludViiV HealthcareUkendtHiv | HIV-1-infektionArgentina
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... og andre samarbejdspartnereAfsluttetHIV-1Burkina Faso, Zambia
-
Hospital Universitari Vall d'Hebron Research InstituteGilead SciencesAfsluttet
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixaAfsluttet
-
Gilead SciencesAfsluttet
-
University of AarhusAarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry...Afsluttet
-
Tibotec Pharmaceuticals, IrelandAfsluttetHIV-1Forenede Stater, Frankrig, Spanien, Portugal, Canada, Det Forenede Kongerige, Sydafrika, Argentina, Brasilien, Puerto Rico, Thailand, Holland, Rumænien
-
Tibotec Pharmaceuticals, IrelandAfsluttetHIV-1Forenede Stater, Canada, Frankrig, Belgien, Tyskland, Spanien, Argentina, Chile, Panama, Brasilien, Puerto Rico, Thailand, Mexico, Australien
-
Mymetics CorporationInstitut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma... og andre samarbejdspartnereAfsluttet
-
Janssen Pharmaceutica N.V., BelgiumAfsluttetHIV-1Forenede Stater, Spanien